Loading cancer entity…
Loading cancer entity…
Clinical trials
68 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03001349 | 68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors | terminated | Early Phase 1 | 4 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 15, 2021 | clinicaltrials |
| NCT00947167 | A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors | terminated | Phase 2 | 4 | Pamela L. KunzOTHER | 1 | Mar 3, 2017 | clinicaltrials |
Showing 1–2 of 2 studies
Data updated 23 days agoSource updated Feb 15, 2021source: clinicaltrials